Lynxcare Clinical Informatics
ActiveSummary
Lynxcare Clinical Informatics has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-417k) and a net result of €-2.76M. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 14% of 1424 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Credit check for your own amount and term
Signals
Checked, nothing found (2)
Financials · fiscal year 2025, full schema
Filed annual accounts As filed with the NBB · 2025 against 2024 · 58 lines
The notes to these accounts (22 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | €300k | - |
| Remuneration, social security and pensions62 | €1.29M | €1.88M | €2.64M | €1.45M | €1.20M | ▼ 17.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €441k | €503k | €501k | €589k | €623k | ▲ 5.8% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €24k | €0 | ▼ 100% |
| Other operating charges640/8 | €6k | €3k | €2k | €5k | €6k | ▲ 16.2% |
| Non-recurring operating charges66A | - | - | €200k | €1.14M | €11k | ▼ 99.0% |
| Gross operating margin9900 | €-751k | €-1.61M | €-2.66M | €-2.79M | €-906k | ▲ 67.5% |
| Operating profit (loss)9901 | €-2.49M | €-3.99M | €-6.00M | €-6.00M | €-2.75M | ▲ 54.2% |
| Financial income75/76B | €514 | - | €69k | €49k | €11k | ▼ 77.8% |
| Recurring financial income75 | €514 | - | €69k | €49k | €11k | ▼ 77.8% |
| Financial charges65/66B | €32k | €319k | €440k | €77k | €28k | ▼ 64.1% |
| Recurring financial charges65 | €32k | €319k | €82k | €77k | €28k | ▼ 64.1% |
| Non-recurring financial charges66B | - | - | €358k | €0 | - | - |
| Profit (loss) for the period before taxes9903 | €-2.52M | €-4.31M | €-6.37M | €-6.03M | €-2.76M | ▲ 54.1% |
| Income taxes67/77 | €789 | €1k | €714 | €274 | €176 | ▼ 35.7% |
| Profit (loss) for the period9904 | €-2.52M | €-4.31M | €-6.37M | €-6.03M | €-2.76M | ▲ 54.1% |
| Profit (loss) for the period to be appropriated9905 | €-2.52M | €-4.31M | €-6.37M | €-6.03M | €-2.76M | ▲ 54.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €2.81M | €15.37M | €8.80M | €2.15M | €1.60M | ▼ 25.7% |
| Fixed assets21/28 | €1.39M | €1.81M | €1.45M | €480k | €186k | ▼ 61.3% |
| Intangible fixed assets21 | €1.35M | €1.39M | €1.39M | €437k | €148k | ▼ 66.1% |
| Tangible fixed assets22/27 | €15k | €23k | €15k | €6k | €156 | ▼ 97.2% |
| Plant, machinery and equipment23 | - | €22k | €14k | €6k | €156 | ▼ 97.2% |
| Furniture and vehicles24 | €15k | €791 | €333 | €0 | - | - |
| Financial fixed assets28 | €21k | €390k | €42k | €38k | €38k | = |
| Current assets29/58 | €1.42M | €13.56M | €7.35M | €1.67M | €1.41M | ▼ 15.5% |
| Amounts receivable within one year40/41 | €997k | €491k | €1.28M | €906k | €878k | ▼ 3.1% |
| Trade receivables40 | €672k | €376k | €838k | €565k | €736k | ▲ 30.3% |
| Other amounts receivable41 | €325k | €116k | €437k | €341k | €142k | ▼ 58.4% |
| Current investments50/53 | - | - | €3.00M | €0 | - | - |
| Cash at bank and in hand54/58 | €424k | €13.05M | €3.03M | €607k | €516k | ▼ 15.0% |
| Deferred charges and accrued income490/1 | €2k | €13k | €45k | €157k | €17k | ▼ 89.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €2.81M | €15.37M | €8.80M | €2.15M | €1.60M | ▼ 25.7% |
| Equity10/15 | €-2.35M | €12.54M | €6.37M | €345k | €-417k | ▼ 221% |
| Contributions10/11 | €2.07M | €21.28M | €12.74M | €12.74M | €2.35M | ▼ 81.6% |
| Capital10 | €1.97M | €21.18M | €12.64M | €12.64M | €2.24M | ▼ 82.2% |
| Issued capital100 | €1.97M | €21.18M | €12.64M | €12.64M | €2.24M | ▼ 82.2% |
| Outside capital11 | €104k | €104k | €104k | €104k | €104k | = |
| Share premium1100/10 | €104k | €104k | €104k | €104k | €104k | = |
| Profit (loss) carried forward14 | €-4.43M | €-8.74M | €-6.37M | €-12.40M | €-2.77M | ▲ 77.7% |
| Amounts payable17/49 | €5.17M | €2.82M | €2.43M | €1.80M | €2.01M | ▲ 11.7% |
| Amounts payable after more than one year17 | €3.85M | €230k | €81k | €3k | €0 | ▼ 100% |
| Financial debts170/4 | €3.85M | €224k | €75k | €3k | €0 | ▼ 100% |
| Other amounts payable178/9 | - | €6k | €6k | €0 | - | - |
| Amounts payable within one year42/48 | €805k | €2.37M | €2.05M | €1.75M | €1.98M | ▲ 13.1% |
| Current portion of amounts payable after more than one year42 | €161k | €869k | €149k | €72k | €3k | ▼ 95.4% |
| Financial debts43 | €200k | €200k | €200k | €200k | €450k | ▲ 125% |
| Credit institutions430/8 | €200k | €200k | €200k | €200k | €450k | ▲ 125% |
| Trade debts44 | €203k | €838k | €1.24M | €1.22M | €1.40M | ▲ 14.5% |
| Suppliers440/4 | €203k | €838k | €1.24M | €1.22M | €1.40M | ▲ 14.5% |
| Advances received on contracts in progress46 | - | - | - | €150k | €0 | ▼ 100% |
| Taxes, remuneration and social security45 | €235k | €462k | €463k | €108k | €128k | ▲ 18.8% |
| Taxes450/3 | €52k | €40k | €53k | €12k | €22k | ▲ 92.4% |
| Remuneration and social security454/9 | €182k | €422k | €410k | €96k | €106k | ▲ 9.9% |
| Other amounts payable47/48 | €5k | - | - | - | - | - |
| Accrued charges and deferred income492/3 | €514k | €225k | €302k | €50k | €34k | ▼ 30.6% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €-2.52M | €-4.31M | €-6.37M | €-6.03M | €-2.76M | ▲ 54.1% |
| + Depreciation and write-downs630 | €441k | €503k | €501k | €589k | €623k | ▲ 5.8% |
| Operating cash flow (approximation) | €-2.08M | €-3.81M | €-5.87M | €-5.44M | €-2.14M | ▲ 60.6% |
| Investment in fixed assets (approximation) | - | €-923k | €-142k | €381k | €-329k | ▼ 186% |
| Change in cash | - | €12.63M | €-10.02M | €-2.43M | €-91k | ▲ 96.3% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
31-07
State Gazette act
Resignation: Melissa West (director)Appointments: Jan Frens VAN GIESSEL (director) and Grant Thornton Bedrijfsrevisoren (statutory auditor) · Capital · Capital increase14 facts ▸
- General meeting, 16/07/2026
- General meeting, 11/06/2025
- Capital, €5.874.509,34
- Capital increase, €2.000.000,01
- Capital increase, €1.629.777,38
- Share issue, Soort C Anti-dilutie Inschrijvingsrechten, 15
- Share issue, Soort C Schadevergoedingsinschrijvingsrechten, 25
- Share issue, ESOP Inschrijvingsrechten, 3.064.790
- Statutes amendment
- Statutes amendment
- Director resignation, Melissa West (director)
- Director appointment, Jan Frens VAN GIESSEL (director)
- +2 further facts in this act
19-03
State Gazette act
Resignations: Heran Partners BV, Dries Hens and 2 othersAppointments: Dries Hens, Charles Christian SCHUETZ and 4 others · Permanent representatives: Katleen Vandersmissen, Robert Vassoyan and 2 others · Capital25 facts ▸
- General meeting, 13-03-2026
- Capital, €2.244.731,95
- Share issue, Inschrijvingsrechtenplan op aandelen 2026, ESOP Inschrijvingsrechten
- Capital increase
- Director resignation, Heran Partners BV (director)
- Director resignation, Dries Hens (director)
- Director resignation, Samantha Jerusalmy (director)
- Director resignation, Vassoyan Conseil SAS (director)
- Director appointment, Dries Hens (director)
- Director appointment, Charles Christian SCHUETZ (director)
- Director appointment, Heran Partners BV (director)
- Director appointment, Vassoyan Conseil SAS (director)
- +13 further facts in this act
Show earlier events
About the unread acts
Of the 20 Belgian State Gazette acts we know for this company, 2 have been read. The other 18 have not been read yet: what they contain is neither established nor disproved here.
Directors · office · real estate
Not every act has been read: a resignation may be missing here
1 establishment unit
2 parcels
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24502B0318/02R000 | Flanders | 751 m² | 1 · 745 m² | 17.8 m · 4 fl. |
| 24302D0015/00Y002 | Flanders | 300 m² | 1 · 159 m² | 12.0 m · 3 fl. |
Linked by address, not proof of ownership
Statutory auditor
1 auditor| Grant Thornton bedrijfsrevisorenCurrent Auditor · represented by Nicolas Dumonceau | 31-07-2026 → present |
Articles of association
Full purpose
1. de verwerking, het beheer en de opslag van informatie binnen de medische sector... 2. Alle mogelijke verrichtingen en activiteiten in verband met ontwikkeling, onderzoek, productie... 3. Wetenschappelijke adviesverlening... a) ... onroerend vermogen... b) ... roerend vermogen... c) ... leningen, kredieten...
Structure & network
Connections & network
2 connected companiesCapital and shareholders
- 31-07-2026 Capital increase of 2,000,000.01 EUR · to 4,244,731.96 EUR · in cash
- 31-07-2026 Capital increase of 1,629,777.38 EUR · to 5,874,509.34 EUR · in kind
- 19-03-2026 Capital stated in the act · 2,244,731.95 EUR · 20,864,891 shares
Public money · subsidies and aid
Flemish government
2023 to 2025 · 7 entries · 872,700 EUR awarded · 486,318 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 2 | 386,382 EUR | 96,752 EUR |
| 2024 | 2 | 1,661 EUR | 191,661 EUR |
| 2023 | 3 | 484,657 EUR | 197,905 EUR |
Similar companies · same sector, comparable size
Identification & contact
Scores and ratios are computed by Checked and are not a credit decision.